Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: A monoinstitutional experience

Elisa De Carlo, Maria Chiara Del Savio, Jerry Polesel, Valentina Da Ros, Eleonora Berto, Sandra Santarossa, Emanuela Chimienti, Lucia Fratino, Alessandra Bearz

Research output: Contribution to journalArticle

Abstract

Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has yet to be determined. Our retrospective study has investigated the outcome of 40 ALK-rearranged NSCLC patients treated with two different sequential strategies in our Institute; a "classical group", treated with crizotinib followed by second or third generation ALKis, and the "experimental group", treated upfront with a second generation ALK inhibitor. The primary endpoints investigated were Progressionfree survival (PFS) and intracranial activity. The analysis has revealed a significant improvement in PFS (p = 0.050) in the experimental group, furthermore none of these patients developed brain metastasis. There was no statistically significant difference in OS, but all patients in the experimental group were still alive after a median follow up of 15 months. Our retrospective analysis suggests that systemic and intracranial efficacy tends to be better in the experimental group; randomized prospective studies could confirm our observations.

Original languageEnglish
Pages (from-to)15340-15349
Number of pages10
JournalOncotarget
Volume9
Issue number20
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Lung Neoplasms
Non-Small Cell Lung Carcinoma
Survival
Retrospective Studies
anaplastic lymphoma kinase
crizotinib
Prospective Studies
Neoplasm Metastasis
Brain
Genes
Therapeutics

Keywords

  • ALK inhibitors
  • Anaplastic lymphoma kinase (ALK)
  • Brain metastasis
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor : A monoinstitutional experience. / De Carlo, Elisa; Del Savio, Maria Chiara; Polesel, Jerry; Da Ros, Valentina; Berto, Eleonora; Santarossa, Sandra; Chimienti, Emanuela; Fratino, Lucia; Bearz, Alessandra.

In: Oncotarget, Vol. 9, No. 20, 01.01.2018, p. 15340-15349.

Research output: Contribution to journalArticle

@article{428805cf2fe64adcb62f8db344f460e2,
title = "Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: A monoinstitutional experience",
abstract = "Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has yet to be determined. Our retrospective study has investigated the outcome of 40 ALK-rearranged NSCLC patients treated with two different sequential strategies in our Institute; a {"}classical group{"}, treated with crizotinib followed by second or third generation ALKis, and the {"}experimental group{"}, treated upfront with a second generation ALK inhibitor. The primary endpoints investigated were Progressionfree survival (PFS) and intracranial activity. The analysis has revealed a significant improvement in PFS (p = 0.050) in the experimental group, furthermore none of these patients developed brain metastasis. There was no statistically significant difference in OS, but all patients in the experimental group were still alive after a median follow up of 15 months. Our retrospective analysis suggests that systemic and intracranial efficacy tends to be better in the experimental group; randomized prospective studies could confirm our observations.",
keywords = "ALK inhibitors, Anaplastic lymphoma kinase (ALK), Brain metastasis, Non-small cell lung cancer",
author = "{De Carlo}, Elisa and {Del Savio}, {Maria Chiara} and Jerry Polesel and {Da Ros}, Valentina and Eleonora Berto and Sandra Santarossa and Emanuela Chimienti and Lucia Fratino and Alessandra Bearz",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24573",
language = "English",
volume = "9",
pages = "15340--15349",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "20",

}

TY - JOUR

T1 - Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor

T2 - A monoinstitutional experience

AU - De Carlo, Elisa

AU - Del Savio, Maria Chiara

AU - Polesel, Jerry

AU - Da Ros, Valentina

AU - Berto, Eleonora

AU - Santarossa, Sandra

AU - Chimienti, Emanuela

AU - Fratino, Lucia

AU - Bearz, Alessandra

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has yet to be determined. Our retrospective study has investigated the outcome of 40 ALK-rearranged NSCLC patients treated with two different sequential strategies in our Institute; a "classical group", treated with crizotinib followed by second or third generation ALKis, and the "experimental group", treated upfront with a second generation ALK inhibitor. The primary endpoints investigated were Progressionfree survival (PFS) and intracranial activity. The analysis has revealed a significant improvement in PFS (p = 0.050) in the experimental group, furthermore none of these patients developed brain metastasis. There was no statistically significant difference in OS, but all patients in the experimental group were still alive after a median follow up of 15 months. Our retrospective analysis suggests that systemic and intracranial efficacy tends to be better in the experimental group; randomized prospective studies could confirm our observations.

AB - Rearrangement in the anaplastic lymphoma kinase (ALK) gene is one of the oncogenic drivers in non-small cell lung cancer (NSCLC) patients. Several ALK inhibitors (ALKis) have been developed and have demonstrated their efficacy, however the best treatment strategy for ALK positive NSCLC patients has yet to be determined. Our retrospective study has investigated the outcome of 40 ALK-rearranged NSCLC patients treated with two different sequential strategies in our Institute; a "classical group", treated with crizotinib followed by second or third generation ALKis, and the "experimental group", treated upfront with a second generation ALK inhibitor. The primary endpoints investigated were Progressionfree survival (PFS) and intracranial activity. The analysis has revealed a significant improvement in PFS (p = 0.050) in the experimental group, furthermore none of these patients developed brain metastasis. There was no statistically significant difference in OS, but all patients in the experimental group were still alive after a median follow up of 15 months. Our retrospective analysis suggests that systemic and intracranial efficacy tends to be better in the experimental group; randomized prospective studies could confirm our observations.

KW - ALK inhibitors

KW - Anaplastic lymphoma kinase (ALK)

KW - Brain metastasis

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85043975117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043975117&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24573

DO - 10.18632/oncotarget.24573

M3 - Article

AN - SCOPUS:85043975117

VL - 9

SP - 15340

EP - 15349

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -